Key milestones
2004
BIOCORP is founded by Jacques Gardette, initially specializing in plastic injection and filling for the pharmaceutical industry.
2013
Biodôme acquires Keynae, a technology specialist, paving the way for a development strategy focused on connected medical devices.
2015
Stock market listing on Alternext / Euronext.
2019
The software and mechanical R&D departments merge.
Mallya® obtains CE mark 0459 as a Class IIbe medical device.
2020
Commercial launch of Mallya®‘s 1st version.
2022
BIOCORP obtains 510(k) clearance for Mallya® from the U.S. Food & Drug Administration.
2023
BIOCORP joins the Novo Nordisk group.
2024
Mallya® branding is declined considering therapeutic areas (D for diabetes, G for growth hormone…).